130 related articles for article (PubMed ID: 22202125)
21. MYCN oncoprotein targets and their therapeutic potential.
Bell E; Chen L; Liu T; Marshall GM; Lunec J; Tweddle DA
Cancer Lett; 2010 Jul; 293(2):144-57. PubMed ID: 20153925
[TBL] [Abstract][Full Text] [Related]
22. MYCN gene overrepresentation detected in primary neuroblastoma tumour cells without amplification.
Valent A; Le Roux G; Barrois M; Terrier-Lacombe MJ; Valteau-Couanet D; Léon B; Spengler B; Lenoir G; Bénard J; Bernheim A
J Pathol; 2002 Dec; 198(4):495-501. PubMed ID: 12434419
[TBL] [Abstract][Full Text] [Related]
23. NLRR1 enhances EGF-mediated MYCN induction in neuroblastoma and accelerates tumor growth in vivo.
Hossain S; Takatori A; Nakamura Y; Suenaga Y; Kamijo T; Nakagawara A
Cancer Res; 2012 Sep; 72(17):4587-96. PubMed ID: 22815527
[TBL] [Abstract][Full Text] [Related]
24. Loss of caspase-8 expression does not correlate with MYCN amplification, aggressive disease, or prognosis in neuroblastoma.
Fulda S; Poremba C; Berwanger B; Häcker S; Eilers M; Christiansen H; Hero B; Debatin KM
Cancer Res; 2006 Oct; 66(20):10016-23. PubMed ID: 17047064
[TBL] [Abstract][Full Text] [Related]
25. N-Myc differentially regulates expression of MXI1 isoforms in neuroblastoma.
Armstrong MB; Mody RJ; Ellis DC; Hill AB; Erichsen DA; Wechsler DS
Neoplasia; 2013 Dec; 15(12):1363-70. PubMed ID: 24403858
[TBL] [Abstract][Full Text] [Related]
26. The MYCN enigma: significance of MYCN expression in neuroblastoma.
Tang XX; Zhao H; Kung B; Kim DY; Hicks SL; Cohn SL; Cheung NK; Seeger RC; Evans AE; Ikegaki N
Cancer Res; 2006 Mar; 66(5):2826-33. PubMed ID: 16510605
[TBL] [Abstract][Full Text] [Related]
27. Subclassification and individual survival time prediction from gene expression data of neuroblastoma patients by using CASPAR.
Oberthuer A; Kaderali L; Kahlert Y; Hero B; Westermann F; Berthold F; Brors B; Eils R; Fischer M
Clin Cancer Res; 2008 Oct; 14(20):6590-601. PubMed ID: 18927300
[TBL] [Abstract][Full Text] [Related]
28. Expression of NLRR3 orphan receptor gene is negatively regulated by MYCN and Miz-1, and its downregulation is associated with unfavorable outcome in neuroblastoma.
Akter J; Takatori A; Hossain MS; Ozaki T; Nakazawa A; Ohira M; Suenaga Y; Nakagawara A
Clin Cancer Res; 2011 Nov; 17(21):6681-92. PubMed ID: 21908575
[TBL] [Abstract][Full Text] [Related]
29. Transcriptional repression of SKP2 is impaired in MYCN-amplified neuroblastoma.
Muth D; Ghazaryan S; Eckerle I; Beckett E; Pöhler C; Batzler J; Beisel C; Gogolin S; Fischer M; Henrich KO; Ehemann V; Gillespie P; Schwab M; Westermann F
Cancer Res; 2010 May; 70(9):3791-802. PubMed ID: 20424123
[TBL] [Abstract][Full Text] [Related]
30. MYCN in neuronal tumours.
Schwab M
Cancer Lett; 2004 Feb; 204(2):179-87. PubMed ID: 15013217
[TBL] [Abstract][Full Text] [Related]
31. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study.
Moreau LA; McGrady P; London WB; Shimada H; Cohn SL; Maris JM; Diller L; Look AT; George RE
Clin Cancer Res; 2006 Oct; 12(19):5693-7. PubMed ID: 17020972
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma.
Chesler L; Schlieve C; Goldenberg DD; Kenney A; Kim G; McMillan A; Matthay KK; Rowitch D; Weiss WA
Cancer Res; 2006 Aug; 66(16):8139-46. PubMed ID: 16912192
[TBL] [Abstract][Full Text] [Related]
33. Keratoepithelin reverts the suppression of tissue factor pathway inhibitor 2 by MYCN in human neuroblastoma: a mechanism to inhibit invasion.
Becker J; Volland S; Noskova I; Schramm A; Schweigerer LL; Wilting J
Int J Oncol; 2008 Jan; 32(1):235-40. PubMed ID: 18097563
[TBL] [Abstract][Full Text] [Related]
34. Deregulated Wnt/beta-catenin program in high-risk neuroblastomas without MYCN amplification.
Liu X; Mazanek P; Dam V; Wang Q; Zhao H; Guo R; Jagannathan J; Cnaan A; Maris JM; Hogarty MD
Oncogene; 2008 Feb; 27(10):1478-88. PubMed ID: 17724465
[TBL] [Abstract][Full Text] [Related]
35. The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis.
Casalà C; Gil-Guiñón E; Ordóñez JL; Miguel-Queralt S; Rodríguez E; Galván P; Lavarino C; Munell F; de Alava E; Mora J; de Torres C
Carcinogenesis; 2013 Feb; 34(2):268-76. PubMed ID: 23108190
[TBL] [Abstract][Full Text] [Related]
36. Expression of a MYCN-interacting isoform of the tumor suppressor BIN1 is reduced in neuroblastomas with unfavorable biological features.
Tajiri T; Liu X; Thompson PM; Tanaka S; Suita S; Zhao H; Maris JM; Prendergast GC; Hogarty MD
Clin Cancer Res; 2003 Aug; 9(9):3345-55. PubMed ID: 12960121
[TBL] [Abstract][Full Text] [Related]
37. Locoregional MYCN-amplified neuroblastoma.
Morales La Madrid A; Volchenboum S; Gastier-Foster JM; Pyatt R; Liu D; Pytel P; Lavarino C; Rodriguez E; Cohn SL
Pediatr Blood Cancer; 2012 Oct; 59(4):736-8. PubMed ID: 22213566
[TBL] [Abstract][Full Text] [Related]
38. A genome-wide search for promoters that respond to increased MYCN reveals both new oncogenic and tumor suppressor microRNAs associated with aggressive neuroblastoma.
Shohet JM; Ghosh R; Coarfa C; Ludwig A; Benham AL; Chen Z; Patterson DM; Barbieri E; Mestdagh P; Sikorski DN; Milosavljevic A; Kim ES; Gunaratne PH
Cancer Res; 2011 Jun; 71(11):3841-51. PubMed ID: 21498633
[TBL] [Abstract][Full Text] [Related]
39. [Study on MYCN gene amplification and CD44 expression in neuroblastoma].
Hu HL; He LJ
Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318
[TBL] [Abstract][Full Text] [Related]
40. MYCN protein expression as a predictor of neuroblastoma prognosis.
Chan HS; Gallie BL; DeBoer G; Haddad G; Ikegaki N; Dimitroulakos J; Yeger H; Ling V
Clin Cancer Res; 1997 Oct; 3(10):1699-706. PubMed ID: 9815553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]